Medtronic launched its Viaverte basivertebral nerve ablation system and completed the acquisition of SPR Therapeutics, extending its chronic pain offering across the pain care continuum. The combination strengthens Medtronic’s neuromodulation toolkit as the industry seeks alternatives to opioids by addressing underlying pain sources. The move highlights how med-tech players are expanding from devices aimed at symptomatic management to broader interventional strategies intended to reduce long-term burden. Both the launch and the acquisition were positioned as part of an integrated strategy in chronic pain. For hospitals and health systems, the key operational consideration will be adoption pathways—training, workflow integration, and device stocking—alongside evidence generation for durability and long-term outcomes.